Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at Jefferies Group issued their Q2 2018 earnings estimates for shares of Vanda Pharmaceuticals in a research report issued to clients and investors on Thursday. Jefferies Group analyst M. Andrews expects that the biopharmaceutical company will post earnings of ($0.06) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $20.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ FY2019 earnings at $0.81 EPS, FY2020 earnings at $0.59 EPS, FY2021 earnings at $0.96 EPS and FY2022 earnings at $1.91 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative net margin of 9.43% and a negative return on equity of 11.97%. The company had revenue of $44.28 million during the quarter, compared to analyst estimates of $44.00 million. During the same quarter in the previous year, the firm earned $0.08 EPS. The firm’s revenue was up 15.8% compared to the same quarter last year.
Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Oppenheimer set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, October 29th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Finally, Seaport Global Securities started coverage on shares of Vanda Pharmaceuticals in a research note on Friday, January 19th. They set a “buy” rating and a $20.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $21.43.
Shares of Vanda Pharmaceuticals (NASDAQ VNDA) opened at $17.10 on Friday. Vanda Pharmaceuticals has a one year low of $11.90 and a one year high of $18.99. The stock has a market cap of $767.90, a price-to-earnings ratio of -50.29 and a beta of 1.24.
In other news, SVP Gunther Birznieks sold 8,568 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total transaction of $130,747.68. Following the transaction, the senior vice president now owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO James Patrick Kelly sold 9,155 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.35, for a total transaction of $140,529.25. Following the transaction, the chief financial officer now directly owns 144,721 shares in the company, valued at approximately $2,221,467.35. The disclosure for this sale can be found here. In the last three months, insiders have sold 209,483 shares of company stock worth $3,205,205. Corporate insiders own 7.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in VNDA. Teacher Retirement System of Texas acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at about $209,000. Metropolitan Life Insurance Co. NY acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at about $221,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Vanda Pharmaceuticals in the third quarter valued at about $277,000. MetLife Investment Advisors LLC acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at about $308,000. Finally, Voya Investment Management LLC lifted its position in Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 4,605 shares during the last quarter. 88.19% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/18/jefferies-group-weighs-in-on-vanda-pharmaceuticals-inc-s-q2-2018-earnings-vnda-2.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.